Acutaas Chemicals Limited , a leading player in the specialty chemicals sector, has announced significant changes in its leadership structure and employee stock option scheme. These developments come as part of the company's strategic moves to strengthen its management team and align its employee benefits with recent corporate actions.

Leadership Enhancement

The Nomination and Remuneration Committee of Acutaas Chemicals has designated Mr. Abhishek Haribhai Patel as a Senior Management Person, effective July 30, 2025. Mr. Patel, who has been serving as the Vice President - Strategy since January 8, 2024, brings a wealth of experience to this elevated role.

Mr. Patel's association with Acutaas Chemicals dates back to his tenure as Chief Financial Officer from 2018 to 2022, during which he played a pivotal role in the company's successful Initial Public Offering in 2021. His educational background includes a Bachelor's degree in Engineering from Sardar Patel University and an MBA from ICFAI University.

ESOS 2023 Adjustments

In response to the recent 1:2 stock split, with a record date of April 25, 2025, Acutaas Chemicals has made necessary adjustments to its Employee Stock Option Scheme (ESOS) 2023. These changes ensure that the overall value of employee benefits remains unchanged while reflecting the new share structure.

Key adjustments to the ESOS 2023 include:

1. Category I Options:

   • Number of options increased from 1,100 to 2,200
   • Exercise price reduced from Rs. 100.00 to Rs. 50.00 per option

2. Category II Options:

   • Ungranted options increased from 3,34,370 to 6,68,740
   • Exercise price range adjusted from Rs. 10.00-610.00 to Rs. 5.00-305.00 per share

The company emphasized that these adjustments maintain the unchanged overall value of employee benefits and do not require shareholder approval.

Financial Performance

Acutaas Chemicals also released its financial results for the first quarter of FY2026, ended June 30, 2025. The company reported a strong performance with significant year-on-year growth:

Mr. Naresh Patel, Executive Chairman & Managing Director, attributed the robust performance to strong growth in the Pharmaceutical Intermediates business. He also highlighted the company's recent achievement of PMDA GMP certification for both pharma facilities, underscoring its commitment to global compliance and quality.

Strategic Expansion

In a move to strengthen its position in the semiconductor market, Acutaas Chemicals announced a joint venture in South Korea. This strategic partnership is expected to bring the company closer to key semiconductor markets and enhance its portfolio with high-value products tailored for this sector.

As Acutaas Chemicals continues to evolve and expand its operations, these recent developments signal the company's commitment to growth, innovation, and employee welfare. With a strong start to FY2026 and increasing customer engagement across CDMO, battery chemicals, and semiconductors, the company appears well-positioned for continued success in the specialty chemicals industry.

Acutaas Chemicals Limited , a leading manufacturer of advanced pharmaceutical intermediates and specialty chemicals, has announced robust financial results for the first quarter, ended June 30.

Financial Highlights

• Revenue from operations increased by 17.3% year-on-year to ₹2,072.00 crore
• EBITDA margin expanded significantly by 785 basis points to 24.6%
• Net profit surged by 199.6% to ₹440.00 crore
• Earnings per share (EPS) rose to ₹5.41, compared to ₹1.83 in the same quarter of the previous year

Strong Performance Across Segments

The company's growth was primarily driven by a strong performance in its Pharmaceutical Intermediates business. Acutaas Chemicals maintained a healthy export-to-domestic ratio, with exports accounting for 60% of the quarter's revenue and domestic sales contributing 40%.

Operational Achievements

Nareshkumar R. Patel, Executive Chairman & Managing Director of Acutaas Chemicals Limited, commented on the results: "I am happy to share that we've had a strong start to the fiscal year, with Q1 revenue growing 17.3% year-on-year, driven by robust performance in our Pharmaceutical Intermediates business. Both our pharma facilities are now PMDA GMP certified, underscoring our commitment to global compliance and quality."

Strategic Expansion

Mr. Patel also announced a significant strategic move: "We have entered into a joint venture in South Korea which brings us closer to key semiconductor markets and strengthens our portfolio with differentiated, high-value products tailored for this space."

The company's wholly-owned subsidiary, Acutaas Advance Material Limited (AAML), has entered into a joint venture agreement with J & Materials Co. Ltd., a South Korean company. AAML will hold 75% of the share capital in the joint venture company, Indichem Inc., while J & Materials Co. Ltd. will hold the remaining 25%.

Investment in Subsidiary

Acutaas Chemicals has also made a significant investment in its wholly-owned subsidiary, AAML. The company has subscribed to 30,48,780 equity shares of AAML at ₹10 each, with a premium of ₹154 per share, through a rights issue. This investment, not exceeding ₹49.99 crore, is part of a larger commitment to invest up to ₹150.00 crore in AAML through a mix of loans and equity subscriptions.

Utilization of Preferential Issue Proceeds

The company reported complete utilization of the ₹99.10 crore raised through a preferential issue of equity shares allotted on May 31. The funds were allocated as originally planned:

Future Outlook

Mr. Patel expressed confidence in the company's future prospects, stating, "With rising customer engagement across CDMO, battery chemicals, and semiconductors, we step into the fiscal year with strong momentum and confidence to deliver 25% growth with improved margins."

Acutaas Chemicals Limited's strong start to the fiscal year, strategic expansions, and investments in high-growth areas position the company well for continued success in the specialty chemicals sector.